Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism

Craig Schindewolf, Vineet D Menachery, Craig Schindewolf, Vineet D Menachery

Abstract

Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine approaches have shown efficacy in animal models and begun to enter clinical trials. In this review, we summarize the current progress towards a MERS-CoV vaccine and highlight potential roadblocks identified from previous attempts to generate coronavirus vaccines.

Keywords: Middle East respiratory syndrome coronavirus; animal models; coronavirus spike glycoprotein; correlates of immunity; severe acute respiratory syndrome coronavirus; vaccine platforms.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The MERS-CoV spike (S) glycoprotein, a Class I fusion protein and the target of the majority of vaccine candidates, exists naturally in trimer form as shown in this simplified diagram. DPP4: dipeptidyl peptidase 4, the receptor for S. S1: S1 domain of S. S2: S2 domain of S. RBD: receptor binding domain. NTD: N-terminal domain of S1. TMD: transmembrane domain. Structural configurations adapted from [45,46,34].

References

    1. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., Wong S.S., Leung S.Y., Chan K.H., Yuen K.Y. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA. 2005;102:14040–14045. doi: 10.1073/pnas.0506735102.
    1. Trifonov V., Khiabanian H., Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N. Engl. J. Med. 2009;361:115–119. doi: 10.1056/NEJMp0904572.
    1. Gire S.K., Goba A., Andersen K.G., Sealfon R.S., Park D.J., Kanneh L., Jalloh S., Momoh M., Fullah M., Dudas G., et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345:1369–1372. doi: 10.1126/science.1259657.
    1. Baize S., Pannetier D., Oestereich L., Rieger T., Koivogui L., Magassouba N., Soropogui B., Sow M.S., Keita S., De Clerck H., et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 2014;371:1418–1425. doi: 10.1056/NEJMoa1404505.
    1. Snijder E.J., Decroly E., Ziebuhr J. The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. Adv. Virus Res. 2016;96:59–126.
    1. Riski H., Hovi T. Coronavirus infections of man associated with diseases other than the common cold. J. Med. Virol. 1980;6:259–265. doi: 10.1002/jmv.1890060309.
    1. Chan J.F., Lau S.K., To K.K., Cheng V.C., Woo P.C., Yuen K.Y. Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 2015;28:465–522. doi: 10.1128/CMR.00102-14.
    1. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676–679. doi: 10.1126/science.1118391.
    1. Anthony S.J., Gilardi K., Menachery V.D., Goldstein T., Ssebide B., Mbabazi R., Navarrete-Macias I., Liang E., Wells H., Hicks A., et al. Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. mBio. 2017;8 doi: 10.1128/mBio.00373-17.
    1. Menachery V.D., Yount B.L., Jr., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A., Graham R.L., Scobey T., Ge X.Y., Donaldson E.F., et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015;21:1508–1513. doi: 10.1038/nm.3985.
    1. Zumla A., Hui D.S., Perlman S. Middle East respiratory syndrome. Lancet. 2015;386:995–1007. doi: 10.1016/S0140-6736(15)60454-8.
    1. Muller M.A., Corman V.M., Jores J., Meyer B., Younan M., Liljander A., Bosch B.J., Lattwein E., Hilali M., Musa B.E., et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997. Emerg. Infect. Dis. 2014;20:2093–2095. doi: 10.3201/eid2012.141026.
    1. Azhar E.I., El-Kafrawy S.A., Farraj S.A., Hassan A.M., Al-Saeed M.S., Hashem A.M., Madani T.A. Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 2014;370:2499–2505. doi: 10.1056/NEJMoa1401505.
    1. The Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill. 2013;18:20427.
    1. Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses-drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37.
    1. Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J., Johnson R.F., Olinger G.G., Jr., Jahrling P.B., Laidlaw M., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 2014;58:4885–4893. doi: 10.1128/AAC.03036-14.
    1. Public Health England/ISARIC . Treatment of MERS-CoV: Information for Clinicians, Clinical Decision-Making Support for Treatment of MERS-CoV Patients. Public Health England; London, UK: 2015.
    1. Vergara-Alert J., Vidal E., Bensaid A., Segales J. Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus. One Health. 2017;3:34–40. doi: 10.1016/j.onehlt.2017.03.001.
    1. Raj V.S., Mou H., Smits S.L., Dekkers D.H., Muller M.A., Dijkman R., Muth D., Demmers J.A., Zaki A., Fouchier R.A., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi: 10.1038/nature12005.
    1. Peck K.M., Cockrell A.S., Yount B.L., Scobey T., Baric R.S., Heise M.T. Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J. Virol. 2015;89:4696–4699. doi: 10.1128/JVI.03445-14.
    1. Cockrell A.S., Peck K.M., Yount B.L., Agnihothram S.S., Scobey T., Curnes N.R., Baric R.S., Heise M.T. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J. Virol. 2014;88:5195–5199. doi: 10.1128/JVI.03764-13.
    1. Coleman C.M., Matthews K.L., Goicochea L., Frieman M.B. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. Pt 2J. Gen. Virol. 2014;95:408–412. doi: 10.1099/vir.0.060640-0.
    1. Cockrell A.S., Yount B.L., Scobey T., Jensen K., Douglas M., Beall A., Tang X.C., Marasco W.A., Heise M.T., Baric R.S. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat. Microbiol. 2016;2:16226. doi: 10.1038/nmicrobiol.2016.226.
    1. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Gale M.J., Jr., Baric R.S., Enjuanes L., Gallagher T., McCray P.B., Jr., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. USA. 2014;111:4970–4975. doi: 10.1073/pnas.1323279111.
    1. Pascal K.E., Coleman C.M., Mujica A.O., Kamat V., Badithe A., Fairhurst J., Hunt C., Strein J., Berrebi A., Sisk J.M., et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA. 2015;112:8738–8743. doi: 10.1073/pnas.1510830112.
    1. Tao X., Garron T., Agrawal A.S., Algaissi A., Peng B.H., Wakamiya M., Chan T.S., Lu L., Du L., Jiang S., et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J. Virol. 2016;90:57–67. doi: 10.1128/JVI.02009-15.
    1. Li K., Wohlford-Lenane C.L., Channappanavar R., Park J.E., Earnest J.T., Bair T.B., Bates A.M., Brogden K.A., Flaherty H.A., Gallagher T., et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl. Acad. Sci. USA. 2017;114:E3119–E3128. doi: 10.1073/pnas.1619109114.
    1. Du L., He Y., Zhou Y., Liu S., Zheng B.J., Jiang S. The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090.
    1. Zhang N., Jiang S., Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines. 2014;13:761–774. doi: 10.1586/14760584.2014.912134.
    1. Surjit M., Lal S.K. The SARS-CoV nucleocapsid protein: A protein with multifarious activities. Infect. Genet. Evolut. 2008;8:397–405. doi: 10.1016/j.meegid.2007.07.004.
    1. Chang C.K., Lo S.C., Wang Y.S., Hou M.H. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov. Today. 2016;21:562–572. doi: 10.1016/j.drudis.2015.11.015.
    1. Millet J.K., Whittaker G.R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. USA. 2014;111:15214–15219. doi: 10.1073/pnas.1407087111.
    1. Li W., Hulswit R.J.G., Widjaja I., Raj V.S., McBride R., Peng W., Widagdo W., Tortorici M.A., van Dieren B., Lang Y., et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl. Acad. Sci. USA. 2017;114:E8508–E8517. doi: 10.1073/pnas.1712592114.
    1. Pallesen J., Wang N., Corbett K.S., Wrapp D., Kirchdoerfer R.N., Turner H.L., Cottrell C.A., Becker M.M., Wang L., Shi W., et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA. 2017;114:E7348–E7357. doi: 10.1073/pnas.1707304114.
    1. Jiang L., Wang N., Zuo T., Shi X., Poon K.M., Wu Y., Gao F., Li D., Wang R., Guo J., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 2014;6:234ra59. doi: 10.1126/scitranslmed.3008140.
    1. Irigoyen N., Firth A.E., Jones J.D., Chung B.Y., Siddell S.G., Brierley I. High-Resolution Analysis of Coronavirus Gene Expression by RNA Sequencing and Ribosome Profiling. PLoS Pathog. 2016;12:e1005473. doi: 10.1371/journal.ppat.1005473.
    1. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., Collins P.L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA. 2004;101:9804–9809. doi: 10.1073/pnas.0403492101.
    1. Agnihothram S., Gopal R., Yount B.L., Jr., Donaldson E.F., Menachery V.D., Graham R.L., Scobey T.D., Gralinski L.E., Denison M.R., Zambon M., et al. Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J. Infect. Dis. 2014;209:995–1006. doi: 10.1093/infdis/jit609.
    1. Zhu M.S., Pan Y., Chen H.Q., Shen Y., Wang X.C., Sun Y.J., Tao K.H. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol. Lett. 2004;92:237–243. doi: 10.1016/j.imlet.2004.01.001.
    1. Channappanavar R., Zhao J., Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 2014;59:118–128. doi: 10.1007/s12026-014-8534-z.
    1. Wang Y.D., Sin W.Y., Xu G.B., Yang H.H., Wong T.Y., Pang X.W., He X.Y., Zhang H.G., Ng J.N., Cheng C.S., et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 2004;78:5612–5618. doi: 10.1128/JVI.78.11.5612-5618.2004.
    1. Zhao J., Alshukairi A.N., Baharoon S.A., Ahmed W.A., Bokhari A.A., Nehdi A.M., Layqah L.A., Alghamdi M.G., Al Gethamy M.M., Dada A.M., et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci. Immunol. 2017;2 doi: 10.1126/sciimmunol.aan5393.
    1. Deming D., Sheahan T., Heise M., Yount B., Davis N., Sims A., Suthar M., Harkema J., Whitmore A., Pickles R., et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006;3:e525. doi: 10.1371/journal.pmed.0030525.
    1. Tseng C.T., Sbrana E., Iwata-Yoshikawa N., Newman P.C., Garron T., Atmar R.L., Peters C.J., Couch R.B. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7:e35421. doi: 10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492.
    1. Weihofen W.A., Liu J., Reutter W., Saenger W., Fan H. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J. Biol. Chem. 2004;279:43330–43335. doi: 10.1074/jbc.M405001200.
    1. Wang Q., Wong G., Lu G., Yan J., Gao G.F. MERS-CoV spike protein: Targets for vaccines and therapeutics. Antivir. Res. 2016;133:165–177. doi: 10.1016/j.antiviral.2016.07.015.
    1. Hansson M., Nygren P.A., Stahl S. Design and production of recombinant subunit vaccines. (Pt 2)Biotechnol. Appl. Biochem. 2000;32:95–107. doi: 10.1042/BA20000034.
    1. Cao Z., Liu L., Du L., Zhang C., Jiang S., Li T., He Y. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol. J. 2010;7:299. doi: 10.1186/1743-422X-7-299.
    1. Du L., Zhao G., Kou Z., Ma C., Sun S., Poon V.K., Lu L., Wang L., Debnath A.K., Zheng B.J., et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 2013;87:9939–9942. doi: 10.1128/JVI.01048-13.
    1. Mou H., Raj V.S., van Kuppeveld F.J., Rottier P.J., Haagmans B.L., Bosch B.J. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 2013;87:9379–9383. doi: 10.1128/JVI.01277-13.
    1. Burton D.R., Williamson R.A., Parren P.W. Antibody and virus: Binding and neutralization. Virology. 2000;270:1–3. doi: 10.1006/viro.2000.0239.
    1. Ma C., Li Y., Wang L., Zhao G., Tao X., Tseng C.T., Zhou Y., Du L., Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32:2100–2108. doi: 10.1016/j.vaccine.2014.02.004.
    1. Zhang M.Y., Wang Y., Mankowski M.K., Ptak R.G., Dimitrov D.S. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen. Vaccine. 2009;27:857–863. doi: 10.1016/j.vaccine.2008.11.083.
    1. Ma C., Wang L., Tao X., Zhang N., Yang Y., Tseng C.K., Li F., Zhou Y., Jiang S., Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32:6170–6176. doi: 10.1016/j.vaccine.2014.08.086.
    1. Nyon M.P., Du L., Tseng C.K., Seid C.A., Pollet J., Naceanceno K.S., Agrawal A., Algaissi A., Peng B.H., Tai W., et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36:1853–1862. doi: 10.1016/j.vaccine.2018.02.065.
    1. Letarov A.V., Londer Y.Y., Boudko S.P., Mesyanzhinov V.V. The carboxy-terminal domain initiates trimerization of bacteriophage T4 fibritin. Biochem. Biokhimiia. 1999;64:817–823.
    1. Tai W., Zhao G., Sun S., Guo Y., Wang Y., Tao X., Tseng C.K., Li F., Jiang S., Du L., et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375–382. doi: 10.1016/j.virol.2016.10.005.
    1. Lan J., Yao Y., Deng Y., Chen H., Lu G., Wang W., Bao L., Deng W., Wei Q., Gao G.F., et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge. EBioMedicine. 2015;2:1438–1446. doi: 10.1016/j.ebiom.2015.08.031.
    1. Tai W., Wang Y., Fett C.A., Zhao G., Li F., Perlman S., Jiang S., Zhou Y., Du L. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J. Virol. 2017;91:e01651-16. doi: 10.1128/JVI.01651-16.
    1. Coleman C.M., Liu Y.V., Mu H., Taylor J.K., Massare M., Flyer D.C., Smith G.E., Frieman M.B. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32:3169–3174. doi: 10.1016/j.vaccine.2014.04.016.
    1. Coleman C.M., Venkataraman T., Liu Y.V., Glenn G.M., Smith G.E., Flyer D.C., Frieman M.B. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine. 2017;35:1586–1589. doi: 10.1016/j.vaccine.2017.02.012.
    1. Kam Y.W., Kien F., Roberts A., Cheung Y.C., Lamirande E.W., Vogel L., Chu S.L., Tse J., Guarner J., Zaki S.R., et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25:729–740. doi: 10.1016/j.vaccine.2006.08.011.
    1. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342:592–598. doi: 10.1126/science.1243283.
    1. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399. doi: 10.1126/science.1085952.
    1. Jiaming L., Yanfeng Y., Yao D., Yawei H., Linlin B., Baoying H., Jinghua Y., Gao G.F., Chuan Q., Wenjie T. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35:10–18. doi: 10.1016/j.vaccine.2016.11.064.
    1. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 1998;16:867–870. doi: 10.1038/nbt0998-867.
    1. Sardesai N.Y., Weiner D.B. Electroporation delivery of DNA vaccines: Prospects for success. Curr. Opin. Immunol. 2011;23:421–429. doi: 10.1016/j.coi.2011.03.008.
    1. Liu M.A. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011;239:62–84. doi: 10.1111/j.1600-065X.2010.00980.x.
    1. Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Ann. N. Y. Acad. Sci. 1995;772:30–39. doi: 10.1111/j.1749-6632.1995.tb44729.x.
    1. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., Kong W.P., Nabel G.J., Gomez P.L. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol. Sci. 2006;91:610–619. doi: 10.1093/toxsci/kfj169.
    1. Muthumani K., Falzarano D., Reuschel E.L., Tingey C., Flingai S., Villarreal D.O., Wise M., Patel A., Izmirly A., Aljuaid A., et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med. 2015;7:301ra132. doi: 10.1126/scitranslmed.aac7462.
    1. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., Kishko M.G., Arthur J.C., Miura A., Mascola J.R., et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 2005;79:8828–8834. doi: 10.1128/JVI.79.14.8828-8834.2005.
    1. Cayabyab M.J., Kashino S.S., Campos-Neto A. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol. Immunology. 2012;135:216–225. doi: 10.1111/j.1365-2567.2011.03525.x.
    1. Wang L., Shi W., Joyce M.G., Modjarrad K., Zhang Y., Leung K., Lees C.R., Zhou T., Yassine H.M., Kanekiyo M., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 2015;6:7712. doi: 10.1038/ncomms8712.
    1. Chi H., Zheng X., Wang X., Wang C., Wang H., Gai W., Perlman S., Yang S., Zhao J., Xia X. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine. 2017;35:2069–2075. doi: 10.1016/j.vaccine.2017.02.063.
    1. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 1996;8:348–354. doi: 10.1016/S0952-7915(96)80124-5.
    1. Al-Amri S.S., Abbas A.T., Siddiq L.A., Alghamdi A., Sanki M.A., Al-Muhanna M.K., Alhabbab R.Y., Azhar E.I., Li X., Hashem A.M. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci. Rep. 2017;7:44875. doi: 10.1038/srep44875.
    1. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., Vitetta E.S. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988;334:255–258. doi: 10.1038/334255a0.
    1. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: Deployment in sight. Curr. Opin. Immunol. 2011;23:377–382. doi: 10.1016/j.coi.2011.03.006.
    1. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997;239:389–401. doi: 10.1006/viro.1997.8878.
    1. Agnihothram S., Menachery V.D., Yount B.L., Jr., Lindesmith L.C., Scobey T., Whitmore A., Schafer A., Heise M.T., Baric R.S. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. J. Virol. 2018;92:e00027-18. doi: 10.1128/JVI.00027-18.
    1. Zhao J., Mangalam A.K., Channappanavar R., Fett C., Meyerholz D.K., Agnihothram S., Baric R.S., David C.S., Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016;44:1379–1391. doi: 10.1016/j.immuni.2016.05.006.
    1. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 1992;89:10847–10851. doi: 10.1073/pnas.89.22.10847.
    1. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., van Schalkwijk P., van der Kwast T., Wyatt L.S., Moss B., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001;19:3700–3709. doi: 10.1016/S0264-410X(01)00075-5.
    1. Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D., Haagmans B.L., Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 2013;87:11950–11954. doi: 10.1128/JVI.01672-13.
    1. Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., Schmidt J., Becker C., Eickmann M., Becker S., et al. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J. Virol. 2015;89:8651–8656. doi: 10.1128/JVI.00614-15.
    1. Langenmayer M.C., Lulf-Averhoff A.T., Adam-Neumair S., Fux R., Sutter G., Volz A. Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. Biologicals. 2018;54:58–62. doi: 10.1016/j.biologicals.2018.05.004.
    1. Haagmans B.L., van den Brand J.M., Raj V.S., Volz A., Wohlsein P., Smits S.L., Schipper D., Bestebroer T.M., Okba N., Fux R., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351:77–81. doi: 10.1126/science.aad1283.
    1. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., Koblin B.A., Buchbinder S.P., Keefer M.C., Tomaras G.D., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013;369:2083–2092. doi: 10.1056/NEJMoa1310566.
    1. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999;6:1574–1583. doi: 10.1038/sj.gt.3300994.
    1. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., Mbewe B., Pitisuttithum P., Schechter M., Vardas E., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957. doi: 10.1016/j.vaccine.2009.10.145.
    1. Mercier S., Rouard H., Delfau-Larue M.H., Eloit M. Specific antibodies modulate the interactions of adenovirus type 5 with dendritic cells. Virology. 2004;322:308–317. doi: 10.1016/j.virol.2004.01.031.
    1. Kim E., Okada K., Kenniston T., Raj V.S., AlHajri M.M., Farag E.A., AlHajri F., Osterhaus A.D., Haagmans B.L., Gambotto A. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32:5975–5982. doi: 10.1016/j.vaccine.2014.08.058.
    1. Guo X., Deng Y., Chen H., Lan J., Wang W., Zou X., Hung T., Lu Z., Tan W. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145:476–484. doi: 10.1111/imm.12462.
    1. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., Gall J.G. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine. 2007;25:2074–2084. doi: 10.1016/j.vaccine.2006.11.025.
    1. Jung S.Y., Kang K.W., Lee E.Y., Seo D.W., Kim H.L., Kim H., Kwon T., Park H.L., Lee S.M., Nam J.H. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine. 2018;36:3468–3476. doi: 10.1016/j.vaccine.2018.04.082.
    1. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., Marsh J., Ertl H.C., Wilson J.M. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 2001;75:11603–11613. doi: 10.1128/JVI.75.23.11603-11613.2001.
    1. Ledgerwood J.E., DeZure A.D., Stanley D.A., Coates E.E., Novik L., Enama M.E., Berkowitz N.M., Hu Z., Joshi G., Ploquin A., et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N. Engl. J. Med. 2017;376:928–938. doi: 10.1056/NEJMoa1410863.
    1. Alharbi N.K., Padron-Regalado E., Thompson C.P., Kupke A., Wells D., Sloan M.A., Grehan K., Temperton N., Lambe T., Warimwe G., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788. doi: 10.1016/j.vaccine.2017.05.032.
    1. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect. Immunity. 1999;67:4780–4786.
    1. Zhang Y., Feng L., Li L., Wang D., Li C., Sun C., Li P., Zheng X., Liu Y., Yang W., et al. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Hum. Vaccines Immunother. 2015;11:1803–1813. doi: 10.1080/21645515.2015.1042193.
    1. Munster V.J., Wells D., Lambe T., Wright D., Fischer R.J., Bushmaker T., Saturday G., van Doremalen N., Gilbert S.C., de Wit E., et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2:28. doi: 10.1038/s41541-017-0029-1.
    1. Zuniga A., Wang Z., Liniger M., Hangartner L., Caballero M., Pavlovic J., Wild P., Viret J.F., Glueck R., Billeter M.A., et al. Attenuated measles virus as a vaccine vector. Vaccine. 2007;25:2974–2983. doi: 10.1016/j.vaccine.2007.01.064.
    1. Malczyk A.H., Kupke A., Prufer S., Scheuplein V.A., Hutzler S., Kreuz D., Beissert T., Bauer S., Hubich-Rau S., Tondera C., et al. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J. Virol. 2015;89:11654–11667. doi: 10.1128/JVI.01815-15.
    1. Bodmer B.S., Fiedler A.H., Hanauer J.R.H., Prufer S., Muhlebach M.D. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 2018;521:99–107. doi: 10.1016/j.virol.2018.05.028.
    1. Kim S.H., Samal S.K. Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines. Viruses. 2016;8:183. doi: 10.3390/v8070183.
    1. Liu R.-Q., Ge J.-Y., Wang J.-L., Yu S., Zhang H.-L., Wang J.-L., Wen Z.-Y., Bu Z.-G. Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels. J. Integr. Agric. 2017;16:2264–2273. doi: 10.1016/S2095-3119(17)61660-5.
    1. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol. Med. 2004;10:210–216. doi: 10.1016/j.molmed.2004.03.003.
    1. Liu R., Wang J., Shao Y., Wang X., Zhang H., Shuai L., Ge J., Wen Z., Bu Z. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antivir. Res. 2018;150:30–38. doi: 10.1016/j.antiviral.2017.12.007.
    1. Willet M., Kurup D., Papaneri A., Wirblich C., Hooper J.W., Kwilas S.A., Keshwara R., Hudacek A., Beilfuss S., Rudolph G., et al. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. J. Infect. Dis. 2015;212(Suppl. 2):S414–S424. doi: 10.1093/infdis/jiv251.
    1. Wirblich C., Coleman C.M., Kurup D., Abraham T.S., Bernbaum J.G., Jahrling P.B., Hensley L.E., Johnson R.F., Frieman M.B., Schnell M.J. One-Health: A Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J. Virol. 2017;91:e02040-16. doi: 10.1128/JVI.02040-16.
    1. Zeltins A. Construction and characterization of virus-like particles: A review. Mol. Biotechnol. 2013;53:92–107. doi: 10.1007/s12033-012-9598-4.
    1. Wang C., Zheng X., Gai W., Zhao Y., Wang H., Feng N., Chi H., Qiu B., Li N., Wang T., et al. MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget. 2017;8:12686–12694. doi: 10.18632/oncotarget.8475.
    1. Wang C., Zheng X., Gai W., Wong G., Wang H., Jin H., Feng N., Zhao Y., Zhang W., Li N., et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antivir. Res. 2017;140:55–61. doi: 10.1016/j.antiviral.2016.12.019.
    1. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011;85:12201–12215. doi: 10.1128/JVI.06048-11.
    1. Agrawal A.S., Tao X., Algaissi A., Garron T., Narayanan K., Peng B.H., Couch R.B., Tseng C.T. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccines Immunother. 2016;12:2351–2356. doi: 10.1080/21645515.2016.1177688.
    1. Deng Y., Lan J., Bao L., Huang B., Ye F., Chen Y., Yao Y., Wang W., Qin C., Tan W. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg. Microbes Infect. 2018;7:60. doi: 10.1038/s41426-018-0056-7.
    1. Iwata-Yoshikawa N., Uda A., Suzuki T., Tsunetsugu-Yokota Y., Sato Y., Morikawa S., Tashiro M., Sata T., Hasegawa H., Nagata N. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 2014;88:8597–8614. doi: 10.1128/JVI.00983-14.
    1. Plotkin S.A. Vaccines: Past, present and future. Nat. Med. 2005;11(Suppl. 4):S5–S11. doi: 10.1038/nm1209.
    1. Ruch T.R., Machamer C.E. The coronavirus E protein: Assembly and beyond. Viruses. 2012;4:363–382. doi: 10.3390/v4030363.
    1. Lamirande E.W., DeDiego M.L., Roberts A., Jackson J.P., Alvarez E., Sheahan T., Shieh W.J., Zaki S.R., Baric R., Enjuanes L., et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J. Virol. 2008;82:7721–7724. doi: 10.1128/JVI.00304-08.
    1. Almazan F., DeDiego M.L., Sola I., Zuniga S., Nieto-Torres J.L., Marquez-Jurado S., Andres G., Enjuanes L. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio. 2013;4:e00650-13. doi: 10.1128/mBio.00650-13.
    1. Graham R.L., Becker M.M., Eckerle L.D., Bolles M., Denison M.R., Baric R.S. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat. Med. 2012;18:1820–1826. doi: 10.1038/nm.2972.
    1. Zust R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., Szretter K.J., Baker S.C., Barchet W., Diamond M.S., et al. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011;12:137–143. doi: 10.1038/ni.1979.
    1. Menachery V.D., Yount B.L., Jr., Josset L., Gralinski L.E., Scobey T., Agnihothram S., Katze M.G., Baric R.S. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-o-methyltransferase activity. J. Virol. 2014;88:4251–4264. doi: 10.1128/JVI.03571-13.
    1. Menachery V.D., Gralinski L.E., Mitchell H.D., Dinnon K.H., III, Leist S.R., Yount B.L., Jr., McAnarney E.T., Graham R.L., Waters K.M., Baric R.S. Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. J. Virol. 2018;92:e00710-18. doi: 10.1128/JVI.00710-18.
    1. Menachery V.D., Gralinski L.E., Mitchell H.D., Dinnon K.H., III, Leist S.R., Yount B.L., Jr., Graham R.L., McAnarney E.T., Stratton K.G., Cockrell A.S., et al. Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. mSphere. 2017;2:e00346-17. doi: 10.1128/mSphere.00346-17.
    1. Liu D.X., Fung T.S., Chong K.K., Shukla A., Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antivir. Res. 2014;109:97–109. doi: 10.1016/j.antiviral.2014.06.013.
    1. Menachery V.D., Mitchell H.D., Cockrell A.S., Gralinski L.E., Yount B.L., Jr., Graham R.L., McAnarney E.T., Douglas M.G., Scobey T., Beall A., et al. MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. mBio. 2017;8 doi: 10.1128/mBio.00665-17.
    1. World Health Organization . Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome (SARS) World Health Organization; Geneva, Switzerland: 2003.
    1. Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L., Jiang S. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014;16:529–531. doi: 10.1016/j.micinf.2014.05.002.
    1. Prescott J., Falzarano D., de Wit E., Hardcastle K., Feldmann F., Haddock E., Scott D., Feldmann H., Munster V.J. Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques. Front. Immunol. 2018;9:205. doi: 10.3389/fimmu.2018.00205.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi